We have loads of redundancy, and dedicated "test in production" machines/datacenters to test actual production loads in actual production-scale sets machines.
Now, tests in production usually involves a pair of hands and 2 other people looking behind (dev + ops + dba), and requires a well defined rollback procedure and post-mortem. We still have absurdly high SLA (99.999%).
If you have enough processes/threads running, the CPU scheduler should take care of that , no?
Leaving that aside, async is very advisable (even a must) if your backend throws requests against external and potentially blocking services and you want to keep answering your own clients without scaling for no reason.
From a Reuters article on it: They also argue that Title 21, subchapter F of the FDA’s own regulations stipulates that the agency “is to make ‘immediately available’ all documents underlying licensure of a vaccine."
So it really sounds like this is just part of the course of making sausage of approval. You have someone already embedded in the licensure project/process where this is all (very likely largely automagically) handled as it is always expected to be released to the public.
A lot of cash was dumped into fast and extensive R&D, trials and production scaling because of the urgency of the situation, and along comes an insane documentation backlog.
To put in perspective, the original HPV vaccine R&D and trial spanned over 7 years with 25,000 patients (of which only 20,000 women), and assuming the documentation was provided to the FDA as it was produced, it could be FOIA'd relatively quickly.
Pfizer/BioNTech did the same, with almost double the patients, in just over 6 months.
Damned if you do, damned if you don't.
What does that even mean?
[0]https://www.fer.xyz/2021/11/software-kintsugi